BlackRock Advisors’s Eyegate Pharmaceuticals, Inc. Warrants EYEGW Stock Holding History

BlackRock Advisors’s Portfolio EYEGW Stock Details EYEGW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$14K	Hold	46,688	–	–	﹤0.01%	3523
2016 Q3	$16K	Hold	46,688	–	–	﹤0.01%	3502
2016 Q2	$1K	Hold	46,688	–	–	﹤0.01%	3743
2016 Q1	$35K	Hold	46,688	–	–	﹤0.01%	3276
2015 Q4	$35K	Buy	46,688 +40,782	+691%	+$34.2K	﹤0.01%	3332
2015 Q3	$6K	Buy	+5,906	New	+$7.3K	﹤0.01%	3699

Other funds holding EYEGW

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VIA

Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return

BlackRock Advisors's EYEGW Position: Q4 2016 in Review

BlackRock Advisors held its Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) position steady in Q4 2016 at 46,688 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #3523.

BlackRock Advisors first reported a position in EYEGW in Q3 2015 and has held it in 6 quarters since. The position peaked at $35K in Q1 2016. 6 funds tracked by Wall St. Rank hold EYEGW as of Q4 2016.

BlackRock Advisors held 46,688 shares of Eyegate Pharmaceuticals, Inc. Warrants worth $14K as of Q4 2016.
BlackRock Advisors left its Eyegate Pharmaceuticals, Inc. Warrants share count unchanged in Q4 2016.
Eyegate Pharmaceuticals, Inc. Warrants made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3523 holding.
BlackRock Advisors first reported a position in Eyegate Pharmaceuticals, Inc. Warrants in Q3 2015 and has held it in 6 quarters since.
BlackRock Advisors's Eyegate Pharmaceuticals, Inc. Warrants position peaked at $35K in Q1 2016.
6 funds tracked by Wall St. Rank held Eyegate Pharmaceuticals, Inc. Warrants as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.